Japanese Pharmaceuticals Adopt Genedata Software for R&D Activities

Astellas, Chugai, and Takeda Among Newly-signed Customers in Japan

Basel, Switzerland, May 20, 2009

Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, announces that over the last year major Japanese pharmaceutical companies have licensed the Genedata Screener® and Genedata Expressionist® enterprise systems for their internal R&D processes. The Genedata Tokyo office has been expanded to support the growing customer base in Japan.

Newly signed customers include Astellas Pharma, Asubio, Chugai Pharmaceutical Co.,Takeda Pharmaceutical Co., as well as several other pharmaceutical and biotechnology companies. Academic institutions using Genedata include Hyogo College of Medicine, NCC Japan and Tokyo University. These leading enterprises are among the more than 50% of the top 50 pharmaceutical companies worldwide using Genedata enterprise systems for improving R&D efficiency.

“Many Genedata users switched from other software providers to Genedata due to our superior product quality, in particular the system’s scalability and flexibility,” said Dr. Othmar Pfannes, CEO of Genedata.

Workflow-based high throughput screening, high content screening and omics molecular profiling activities are efficiently combined with target management and systems biology in a customizable enterprise system. Designed for easy, in-house integration by bioinformaticians and IT experts, Genedata software supports highly innovative R&D processes, facilitates the introduction of SOPs for knowledge generation, and can be accessed and shared across an organization. Domain experts and managers can combine disparate techniques to find biomarkers for patient stratification, compound profiling or molecular diagnostics. Techniques may include:

  • Mass spectrometry, microarray and 2D-Gel expression analysis

  • High throughput screening and high content screening

  • Clinical chemistry, histopathology and related data

“Building on the tremendous success of the previous twelve months, we are committed to further expanding Genedata’s presence in Japan and other Asian markets,” continued Dr. Pfannes. “Delivering cutting-edge software applications and services distinguishes Genedata from our competition. We look forward to a continued collaboration with our partners and generating value for their R&D operations.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com

Contact
Allison Kurz
Genedata
Marketing & Communications
Phone: +41 61 511 8459
communications@genedata.com

Jackie Thrasivoulos
Genedata
Public Relations
Phone: +1 508 881 3109
jackie.thrasivoulos@genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.